Corium International Inc (NASDAQ:CORI)‘s stock had its “buy” rating reiterated by stock analysts at Jefferies Group LLC in a report released on Friday. They presently have a $8.00 target price on the biopharmaceutical company’s stock. Jefferies Group LLC’s target price suggests a potential upside of 120.39% from the company’s current price.

Other analysts have also recently issued research reports about the company. Cantor Fitzgerald set a $10.00 price target on Corium International and gave the stock a “buy” rating in a research report on Tuesday, February 14th. FBR & Co set a $12.00 price target on Corium International and gave the stock a “buy” rating in a research report on Tuesday, February 14th. Needham & Company LLC lowered their price target on Corium International from $12.00 to $10.00 and set a “buy” rating for the company in a research report on Tuesday, February 14th. Leerink Swann reaffirmed a “buy” rating on shares of Corium International in a research report on Wednesday, January 4th. Finally, Zacks Investment Research raised Corium International from a “sell” rating to a “hold” rating in a research report on Thursday, February 16th. Two research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus price target of $10.21.

Analyst Recommendations for Corium International (NASDAQ:CORI)

Shares of Corium International (NASDAQ:CORI) opened at 3.63 on Friday. The stock’s market cap is $106.08 million. Corium International has a 52-week low of $2.67 and a 52-week high of $8.33. The company’s 50 day moving average price is $3.51 and its 200 day moving average price is $4.61.

Corium International (NASDAQ:CORI) last issued its quarterly earnings results on Monday, February 13th. The biopharmaceutical company reported ($0.46) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.42) by $0.04. Corium International had a negative return on equity of 359.24% and a negative net margin of 116.26%. The firm had revenue of $7 million for the quarter, compared to analyst estimates of $8.07 million. On average, analysts anticipate that Corium International will post ($1.59) earnings per share for the current year.

Your IP Address:

A hedge fund recently bought a new stake in Corium International stock. Senzar Asset Management LLC acquired a new stake in shares of Corium International Inc (NASDAQ:CORI) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 1,576,766 shares of the biopharmaceutical company’s stock, valued at approximately $6,402,000. Corium International comprises about 1.7% of Senzar Asset Management LLC’s investment portfolio, making the stock its 18th largest position. Senzar Asset Management LLC owned about 5.40% of Corium International at the end of the most recent quarter. Institutional investors and hedge funds own 67.75% of the company’s stock.

About Corium International

Corium International, Inc is a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty pharmaceutical products. As of September 30, 2016, the Company had multiple programs in preclinical and clinical development focused primarily on the treatment of neurological disorders, with two lead programs in Alzheimer’s disease.

5 Day Chart for NASDAQ:CORI

Receive News & Stock Ratings for Corium International Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corium International Inc and related stocks with our FREE daily email newsletter.